Standout Papers

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease 2018 2026 2020 2023 465
  1. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease (2018)
    Michael Egan, James Kost et al. New England Journal of Medicine
  2. Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease (2019)
    Michael Egan, James Kost et al. New England Journal of Medicine

Immediate Impact

8 from Science/Nature 72 standout
Sub-graph 1 of 18

Citing Papers

Biomarker Changes during 20 Years Preceding Alzheimer’s Disease
2024 Standout
Trigeminal ganglion neurons are directly activated by influx of CSF solutes in a migraine model
2024 StandoutScience
5 intermediate papers

Works of James Kost being referenced

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
2018 Standout
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
2008
and 1 more

Author Peers

Author Last Decade Papers Cites
James Kost 792 992 245 434 34 2.5k
Christine Furtek 574 890 367 54 21 2.3k
Shelia Jin 1230 1450 82 54 27 3.8k
J. M. Orgogozo 969 1362 25 71 40 3.5k
Magdalena Korecka 999 882 199 48 49 2.6k
Tim West 376 984 52 72 61 2.3k
Aarti R. Shah 1445 2350 74 54 40 4.9k
Carl‐Gerhard Gottfries 604 834 52 49 57 2.4k
Jennifer Chen 241 1012 156 37 75 3.2k
Maria Bjerke 1723 2139 38 131 78 4.1k
Valeria Calsolaro 249 1015 35 81 60 2.5k

All Works

Loading papers...

Rankless by CCL
2026